Glenview Doubles Down on Teva Stock With $72 Million Buy, According to Recent SEC Filing

Glenview Capital Management, LLC increased its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 868,457 shares in the third quarter, adding approximately $71.98 million in value, according to a November 14, 2025, SEC filing.Glenview Capital Management reported a net increase of 868,457 shares in Teva Pharmaceutical Industries Limited during the third quarter, according to a filing with the U.S. Securities and Exchange Commission dated November 14, 2025. The position’s value rose to $337.19 million as of September 30, 2025, reflecting price appreciation and additional share accumulation.The fund increased its Teva stake, which now accounts for 7.51% of 13F AUM and ranks as its 4th-largest holding.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool